Drug Trial Radar · NCT05154240
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Feb 21, 2022
Primary completion
Dec 2, 2022
Study completion Dec 2, 2022
Sponsor
- Lead sponsor
- InSilico Medicine Hong Kong LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled, oral single and multiple ascending-doses, parallel group study to evaluate the safety, tolerability and PK of INS018\_055 in healthy subjects. The study will be conducted in 1 clinical site in the New Zealand, consisting of 2 parts: Part A (single ascending dose \[SAD\]) and Part B (multiple ascending dose \[MAD\]).
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
INS018_055Drug
INS018\_055 is a small molecule compound. INS018\_055 has good solubility in water and was chemically and physically stable at different temperatures.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events based on subjective and objective examinationTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NZCR Ltd
Christchurch, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.